Durvalumab (ImfinziTM; AstraZeneca) is a human monoclonal antibody that suppresses PD-L1, prevents it from interacting with PD-1, and increases the cytotoxic and anti-tumor activity of T cells (13). The gene discussed is PDCD1; the disease is neoplasm.